Back to Market Feed

Historical record - last NADAC effective date: 2/17/2021

Product Information

NAPROXEN 250 MG TABLET is a generic product labeled by Cipla USA Inc., priced at $0.0520 per EA under NDC 69097085307. Its NADAC has been published 233 times since Sep 14, 2016.

FDA first approved this application on Aug 24, 2011.

The High Outlier badge above means this manufacturer's average price in the naproxen market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

NAPROXEN 250 MG TABLET

naproxen
$0.0520per EA
High Outlier

Strength

250 mg/1

Manufacturer

Cipla USA Inc.

NDC

69097085307

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

2/17/2021

Active Ingredients

NAPROXEN

Approval Type

Generic (ANDA)

FDA Application

ANDA091305

FDA Approved

8/24/2011

On Market Since

7/5/2016

Pharmacological Classes

Anti-Inflammatory Agents
Non-Steroidal
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug

Price Statistics

The NADAC for NAPROXEN 250 MG TABLET has been published 233 times since Sep 14, 2016, and over the history we have for it it has risen 2.4%. The table below summarizes its recorded NADAC range and movement.

Current price$0.0520 per EA
All-time high$0.0578 (Mar 13, 2019)
All-time low$0.0425 (Jun 20, 2018)
Median price$0.0505
Average price$0.0508
Largest weekly change+16.8% (Sep 23, 2020)
Weeks tracked233
Tracking sinceSep 14, 2016

Price History

1W

N/A

1M

N/A

3M

N/A

6M

N/A

1Y

N/A

3Y

N/A

5Y

N/A

All

+2.4%

Last surveyed Feb 24, 2021 — this NDC no longer appears in the current weekly NADAC file.

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the naproxen market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

MINIPRIN EC 81 MG TABLET
Generic
49483033010•Time-Cap Labs Inc.
$0.0118
per EA
MINIPRIN EC 81 MG TABLET
Generic
49483033012•Time-Cap Labs Inc.
$0.0118
per EA
QC ASPIRIN 325 MG TABLET
Generic
63868035203•Chain Drug Marketing Association
$0.0121
per EA
QC ASPIRIN 325 MG TABLET
Generic
63868035210•Chain Drug Marketing Association
$0.0121
per EA
ST. JOSEPH ASPIRIN EC 81 MG TB
Generic
69536018112•Foundation Consumer Healthcare LLC
$0.0139
per EA
ASPIRIN EC 81 MG TABLET
Generic
00536123441•Rugby Laboratories
$0.0146
per EA
ASPIRIN EC 81 MG TABLET
Generic
00904675180•Major Pharmaceuticals
$0.0146
per EA
ASPIRIN EC 81 MG TABLET
Generic
00904678370•Major Pharmaceuticals
$0.0146
per EA
GNP ASPIRIN EC 81 MG TABLET
Generic
46122059848•AmerisourceBergen
$0.0146
per EA
GNP ASPIRIN EC 81 MG TABLET
Generic
46122059887•AmerisourceBergen
$0.0146
per EA

Frequently asked questions

What is the NADAC price of NAPROXEN 250 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for NAPROXEN 250 MG TABLET, manufactured by Cipla USA Inc., is $0.0520 per EA (NDC 69097085307), effective Feb 24, 2021.

How has the price of NAPROXEN 250 MG TABLET changed over time?

Over the history we have for it, the NADAC for NAPROXEN 250 MG TABLET has risen 2.4%. It has been tracked across 233 weekly CMS publications since Sep 14, 2016.

What are the highest and lowest recorded NADAC prices for NAPROXEN 250 MG TABLET?

Since Sep 14, 2016, the NADAC for NAPROXEN 250 MG TABLET has ranged from a low of $0.0425 (Jun 20, 2018) to a high of $0.0578 (Mar 13, 2019), with a median of $0.0505 per EA.

Are there cheaper alternatives to NAPROXEN 250 MG TABLET?

No other NADAC-published product currently shares the active ingredient and strength of NAPROXEN 250 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures NAPROXEN 250 MG TABLET?

NAPROXEN 250 MG TABLET (NDC 69097085307) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.